Drug intelligence / Profile preview

KV02b

Development stage: Preclinical
Lead developer: Kensana Health
Modality: Small Molecules

Overview

KV02b is a preclinical-stage phytopharmaceutical candidate being developed by Kensana Health for the treatment of second-degree and more severe burns. As a cannabinoid-based therapy, it is designed to modulate the endocannabinoid system (ECS), which is known to play a critical role in skin homeostasis, inflammatory response, and wound repair. By targeting ECS receptors, KV02b aims to accelerate the healing of burn wounds and potentially manage associated pain and inflammation. The program is part of Kensana Health's broader pipeline of standardized, plant-derived cannabinoid therapeutics.

Targets

CB (Cannabinoid receptors)

Beyond the preview

Go deeper on KV02b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KV02b.

Explore the full profile